MIMI I-NAN HU to Bone Density Conservation Agents
This is a "connection" page, showing publications MIMI I-NAN HU has written about Bone Density Conservation Agents.
Connection Strength
2.837
-
Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am. 2021 12; 50(4):721-728.
Score: 0.710
-
Adverse events associated with bone-directed therapies in patients with cancer. Bone. 2022 05; 158:115901.
Score: 0.673
-
Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol. 2015; 11(21):2865-71.
Score: 0.463
-
Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2013 Sep 18; 105(18):1417-20.
Score: 0.401
-
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023 02 15; 108(3):507-528.
Score: 0.193
-
Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer. Oral Dis. 2022 Jan; 28(1):193-201.
Score: 0.166
-
Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014 Sep; 99(9):3144-52.
Score: 0.106
-
Response. J Natl Cancer Inst. 2014 Jul; 106(7).
Score: 0.106
-
Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2011 Feb; 1218:47-54.
Score: 0.020